El estudio muestra cómo modelos 3D de glioblastoma responden a un nanocompuesto activado y analizado con luz de sincrotrón
Read moreTwo researchers from the Centre for Genomic Regulation (CRG) have been recognised in the latest round of the FERO Cancer grants for the pioneering potential of their work to improve the diagnosis and...
Read moreThe researcher will study how the tumour environment influences the response to Pan-KRAS inhibitors, one of the most promising therapeutic strategies against pancreatic ductal adenocarcinoma.
Read moreLa investigación del Centro de Investigación del Cáncer, liderada por Sandra Blanco, explora el potencial del epitranscriptoma para desarrollar nuevos fármacos capaces de mejorar la respuesta a lo...
Read moreIn first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demo...
Read moreThe project aims to determine how genetic alterations affecting the BAF complex, and the epigenetic changes they trigger, contribute to treatment resistance and disease progression.
Read moreEn este artículo se describe un enfoque experimental centrado en el desarrollo de anticuerpos monoclonales dirigidos frente al C‑telopéptido de COL11A1, una región clave pero poco caracterizada. ...
Read moreThe study reveals that drug-induced senescence, as part of therapeutic strategies against cancer, may not always be definitive. In some tumors, “aged” tumor cells can regrow once the drug is remov...
Read moreYeates is the inventor of protein nanoparticles that assemble themselves, much like ‘Lego’ bricks. They are used to visualise very small proteins that are targets for anti-cancer drugs.
Read moreThe PHOENIX project, involving 13 European institutions, will evaluate for the first time in paediatric patients the drug ibrilatazar from AbilityPharma in a phase I/II clinical trial.
Read moreThe HMarBCN -CNIO Cancer Immunotherapy Clinical Research Unit has just received funding from the Deutsche José Carreras Leukämie Stiftung for a project aimed at modifying T cells directly within the...
Read moreGate2Brain signs a strategic partnership with Shilpa Biocare, including a €7 million investment for a 30.4% equity stake in the company.
Read more